Top 3 Stock Picks for 2022

Top 3 Stock Picks for 2022

Wall Street experts reiterate their year’s Top Picks as the second quarter begins. These stocks are most likely to provide the best long-term gains.

These 3 Stocks are picks for 2022: BellRing Brands (BRBR), Churchill Downs (CHDN), MiMedx Group (MDXG)

Analysts have carefully examined each stock; they looked at its historical and current performance, patterns across several time intervals, and management’s objectives — they consider everything. Their ideas can help you develop a more resilient portfolio.

BellRing Brands (BRBR)

The first is BellRing Brands, a well-known Post food corporation subsidiary. BellRing is a manufacturer and marketer of protein shakes, powder mixes and additives, and snack bars, emphasizing active nutrition products.

BellRing reported $306.5 million in revenue in the first quarter of the fiscal year 2022, up 8.5 percent year over year. The company’s earnings per share (EPS) increased by 67% year over year to 25 cents. Investors should be aware that BellRing’s parent firm, Post, has sold its BRBR stock. Who owns roughly 57 percent of BellRing’s outstanding stock.

Churchill Downs (CHDN)

Next up is Churchill Downs, most known for hosting the Kentucky Derby, North America’s most prestigious horse race, held annually since 1875. Churchill Downs is also a parent corporation, with 11,000 slot machines and over 200 games spread throughout eight states. In addition to all of this, Churchill Downs maintains a significant online betting site for horse racing, sports betting, and casino games.

Last year, however, saw a robust recovery as the pandemic subsided, the economy reopened, and people began to spend their saved money – with a high demand for amusement. In 2021, Churchill Downs reported a net income of $249.1 million, a significant improvement. The company generated net revenue of $1.59 billion in the most recent quarter, 4Q21, increasing 52 percent year over year.

MiMedx Group (MDXG)

MiMedx, a pioneer in placental biologics who uses amniotic tissue to develop regenerative therapies, is our final Top Pick. The company has utilized this as a foundation to establish a patent-protected line of placental tissue allografts using a patented technique. It also has a research pipeline to reduce pain and enhance function in degenerative musculoskeletal disease patients. The company is attempting to extend its presence in the wound-care market. MiMedx established a relationship with WoundGenex, a wound care management company, which will make WoundGenex’s Premier Graft available to MiMedx’s client base.